Eledon Pharmaceuticals, Inc.
ELDN
$3.88
-$0.02-0.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.21% | 34.04% | 39.14% | 48.95% | 46.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.96% | 53.80% | 87.40% | 81.65% | 64.13% |
| Operating Income | -17.96% | -53.80% | -87.40% | -81.65% | -64.13% |
| Income Before Tax | -27.49% | -266.27% | 113.89% | 85.61% | 69.32% |
| Income Tax Expenses | -91.88% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.07% | -268.26% | 113.49% | 85.28% | 68.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.07% | -268.26% | 113.49% | 85.28% | 68.95% |
| EBIT | -17.96% | -53.80% | -87.40% | -81.65% | -64.13% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 47.27% | 18.58% | 127.59% | 92.46% | 77.82% |
| Normalized Basic EPS | 43.29% | 20.37% | 119.45% | 94.02% | 79.39% |
| EPS Diluted | 82.71% | 68.38% | 67.24% | 47.32% | 32.37% |
| Normalized Diluted EPS | 48.19% | 25.50% | 116.49% | 92.08% | 77.44% |
| Average Basic Shares Outstanding | 68.30% | 94.89% | 108.34% | 112.06% | 97.99% |
| Average Diluted Shares Outstanding | 65.30% | 90.54% | 111.00% | 115.16% | 101.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |